Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $32.0052W HIGH $43.36
Volume
11.78 K
Value Traded
35.68 K
Short % Float
1.84%
Days to Cover
8.7
+0.58%Week
-3.58%1 Month
-12.74%3 Month
-12.25%6 Month
+235.32%5 Year
+799.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
106.78 M
EPS (TTM)
2.84
P/E Ratio
11.47
Ent. Value
122.37 M
Total Shares
2.90 M
Float Shares
2.15 M
Insiders
25.86%
Institutions
41.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
KEQU Catalyst Timeline
Dated clinical, regulatory and corporate events for Kewaunee Scientific Corporation
Past FDA Catalysts and PDUFA Decisions
How KEQU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Kewaunee Scientific Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every KEQU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Phillips Elizabeth DOfficer (SVP, People & Culture) | Option | 6,656 14,904 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KEQU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in KEQU for Q2 2026. | ||||
Ownership Trends
KEQU Short Interest
Shares sold short, counted twice a month.
1.84%
Short % of Float
of tradable shares sold short
39.6K
Shares Sold Short
-9.9% vs prior count
8.7 High
Days to Cover
trading days of normal volume to buy every short share back
4.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KEQU ranks across every disease it competes in
Competitive Position is a premium feature
See how KEQU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKEQU News
KEQU▲ +11.4%today
Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.
Kewaunee Scientific Corporation announced a definitive agreement to acquire Nycom, Inc., the largest lab dealer in the USA, for $55 million. This acquisition aims to integrate Nycom's laboratory design expertise with Kewaunee's manufacturing capabilities, enhancing their service offerings and market presence. The deal is expected to close in the fourth quarter of fiscal 2027.
Read more →KEQUKewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027
Kewaunee Scientific Corporation reported its first-quarter results for fiscal year 2027, showing a backlog increase to $169 million. Despite a 6.7% decline in sales and a significant drop in pre-tax earnings, the company noted strong international segment performance and effective cost management. The CEO expressed confidence in the company's strategy and market demand.
Read more →KEQUKewaunee Scientific to Report Results for First Quarter Fiscal Year 2027
Kewaunee Scientific Corporation will release its first quarter fiscal year 2027 financial results on September 9, 2026. The company, established in 1906, specializes in laboratory and healthcare furniture and operates globally with multiple manufacturing facilities. The announcement includes forward-looking statements that highlight potential risks and uncertainties affecting future performance.
Read more →KEQUKewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter
Kewaunee Scientific Corporation reported a 17.3% increase in revenue for fiscal year 2026, totaling $281.999 million. Despite this growth, net earnings fell to $9.618 million from $11.405 million the previous year. The company successfully integrated Nu Aire, improving its laboratory products portfolio, but faced challenges in the fourth quarter with a 7.5% drop in sales. Overall, Kewaunee's balance sheet improved significantly, with reduced long-term debt and a stronger equity position.
Read more →KEQUKewaunee Scientific to Report Results for Fiscal Year and Fourth Quarter
Kewaunee Scientific Corporation will release its financial results for the fourth quarter and fiscal year ending April 30, 2026, on June 23, 2026. The company, a leader in laboratory and healthcare furniture, has expanded its portfolio with the acquisition of Nu Aire. The announcement highlights the company's commitment to transparency and growth, despite potential risks associated with forward-looking statements.
Read more →KEQUKewaunee Scientific Corporation Appoints Jorge Santos as Vice President of International Sales, Laboratory Products Group
Kewaunee Scientific Corporation has appointed Jorge Santos as Vice President of International Sales for its Laboratory Products Group. This move aims to enhance the company's growth strategy, particularly in international markets such as India, the Middle East, and Asia Pacific. Santos, an industry veteran, is expected to leverage his extensive experience to support Kewaunee's global expansion efforts.
Read more →KEQUKewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2026
Kewaunee Scientific Corporation reported its third-quarter results for fiscal year 2026, showing a 3.3% increase in sales to $69.4 million. Pre-tax earnings rose significantly by 25.8%, but net earnings fell to $692,000. The company experienced a decline in domestic sales while international sales surged by 21.4%. The order backlog decreased compared to the previous year, reflecting ongoing challenges in the domestic market.
Read more →KEQUKewaunee Scientific and Nu Aire Inc. to Attend analytica 2026 in Munich
Kewaunee Scientific Corporation will attend the analytica 2026 tradeshow in Munich, showcasing its laboratory solutions alongside its subsidiary Nu Aire, Inc. The event, scheduled for March 24-27, aims to connect with over 30,000 industry professionals. The collaboration with ibs tecnomara will further enhance their offerings in laboratory infrastructure and safety solutions.
Read more →KEQUKewaunee Scientific to Report Results for Third Quarter Fiscal Year 2026
Kewaunee Scientific Corporation will announce its third quarter fiscal year 2026 financial results on March 11, 2026. The company, a leader in laboratory and healthcare furniture, has recently acquired Nu Aire, enhancing its product portfolio. The press release also includes forward-looking statements that highlight potential risks and uncertainties affecting future performance.
Read more →KEQUKewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026
Kewaunee Scientific Corporation reported a 46.8% increase in sales for the second quarter of fiscal year 2026, reaching $70.1 million. However, net earnings decreased to $2.4 million, down from $3.0 million in the same quarter last year. The company noted strong performance in its domestic and international segments, although the corporate segment continued to face losses. The order backlog remains robust, indicating potential for future growth despite some volatility in project timelines.
Read more →KEQUKewaunee Scientific Announces Successful Debt Refinancing and Full Repayment of Seller Notes From the Company's Acquisition of Nu Aire, Inc.
Kewaunee Scientific Corporation announced the successful early repayment of its Seller Notes, originally due in 2027, funded through a refinancing deal with PNC Bank. This move reduces the company's debt load and interest expenses, reflecting its commitment to disciplined financial management. The company aims to leverage this flexibility for future growth initiatives.
Read more →KEQUKewaunee Scientific to Report Results for Second Quarter Fiscal Year 2026
Kewaunee Scientific Corporation (NASDAQ: KEQU) plans to release its second quarter fiscal year 2026 financial results on December 10, 2025. The company, known for its laboratory and healthcare products, has recently acquired Nu Aire, enhancing its product offerings. The announcement includes caution regarding forward-looking statements and potential risks that may affect future performance.
Read more →KEQU▼ -21.2%on this news
Kewaunee Scientific Announces Appointment of J. Jette Campbell to Board of Directors
Kewaunee Scientific Corporation has appointed J. Jette Campbell to its Board of Directors, effective September 10, 2025. Campbell, a CPA with extensive experience in guiding organizations through growth, is expected to enhance Kewaunee's strategic direction. His background in the building materials and furniture sectors aligns with the company's objectives for expansion and operational improvement.
Read more →KEQUKewaunee Scientific Reports Results for First Quarter of Fiscal Year 2026
Kewaunee Scientific Corporation reported strong first-quarter results for fiscal year 2026, with sales increasing by 46.9% year-over-year. The company achieved net earnings of $3,093,000, a significant rise from the previous year's $2,193,000. Despite challenges such as project delivery volatility and a corporate segment loss, Kewaunee remains optimistic about future growth through strategic investments.
Read more →KEQUKewaunee Scientific to Attend the 2025 Arablab Live Trade Show in Dubai
Kewaunee Scientific Corporation announced its participation in the 2025 Arablab Live tradeshow in Dubai from September 23-25. The event will feature product demonstrations and insights from Kewaunee's teams and its subsidiary NuAire. Attendees can explore innovative solutions at Kewaunee's booth, including new design tools for laboratory planning.
Read more →KEQUKEWAUNEE SCIENTIFIC CORPORATION NASDAQ: KEQU Special Note Regarding Forward-Looking Statements Certain statements in this document constitute forward-looking statements within the meaning of the Private Securities Litiga
Kewaunee Scientific Corporation (NASDAQ: KEQU) issued a special note regarding forward-looking statements as part of its Annual Report, outlining various risks and uncertainties related to its future performance. Key factors affecting the company's outlook include competitive conditions, changes in customer demands, and operational disruptions. The report highlights a notable decline in net earnings attributed to factors such as professional fees related to acquisitions and pension expenses. Although the report discusses adjusted financial measures, discrepancies between these and standard GAAP measures could lead to confusion among investors.
Read more →KEQUKewaunee Scientific to Report Results for First Quarter Fiscal Year 2026
Kewaunee Scientific Corporation plans to release its first quarter fiscal year 2026 financial results on September 10, 2025. The company, known for its laboratory and healthcare products, has recently acquired Nu Aire, enhancing its product offerings. However, it acknowledges potential risks associated with this acquisition and broader economic conditions.
Read more →KEQUKewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025
Kewaunee Scientific Corporation reported a 43.6% increase in sales for Q3 FY2025, totaling $67.2 million. However, pre-tax earnings fell by 63.7% due to costs related to the acquisition of Nu Aire. The company noted a strong order backlog of $221.6 million, indicating positive future prospects despite challenges in the international segment.
Read more →About Kewaunee Scientific Corporation
Headquarters2700 W FRONT ST, STATESVILLE, NC, 28677
BIOPHARMAWATCH ELITE PLUS
Trade the next KEQU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime